Numbers first: a sterility test · dulaglutide.
This is a planning question. I know what my options are; I do not know how to weigh them.
What I want is the minimum viable version, which I suspect is smaller than what I would design.
What does a sensible plan look like, and what are the decision points?
Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Mechanically, the statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.
If testing multiple vials, state how many you tested and why you chose those vials.
Batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
More usefully, under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 11 Nov 2024 by Dr_Sara_Kuusela — reworded for clarity after a comment
Most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.
Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
I would treat a "complies with" statement without sampling details as a claim rather than as evidence.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Specifically, two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.
If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
If testing multiple vials, state how many you tested and why you chose those vials.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.